Fiche centre
Beijing Anzhen Hospital, Capital Medical University
Beijing — China
Essais liés6clinical trials
VilleBeijinglocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06935370
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Selatogrel | Maladie coronarienne | Phase 3 | NCT04957719 | SOS-AMI — Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | ENROLLING_BY_INVITATION |
| BI 690517 | Maladie rénale chronique | Phase 3 | NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | ACTIVE_NOT_RECRUITING |
| Edoxaban | Accident vasculaire cérébral | Phase 4 | NCT03950076 | EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) | COMPLETED |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | RECRUITING |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06935370 | A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | RECRUITING |
| RC18 160mg | Myasthénie | Phase 2 | NCT04302103 | A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis | COMPLETED |